Monika Jarzabek

Dr. Monika Jarzabek

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2017 in Nature Reviews Cancer
Verified
Journal Article
Open access
PDF file
ABAnnette T Byrne
Annette T Byrne
DADenis G. Alférez
Denis G. Alférez
FAFrédéric Amant
Frédéric Amant
DADaniela Annibali
Daniela Annibali
Joaquín ArribasJoaquín Arribas
Joaquín Arribas
LTLivio Trusolino
Livio Trusolino
Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.

26 July 2011 in Angiogenesis
Verified
Journal Article
Closed access
PDF file
PVPieter Vader
Pieter Vader
RMR. van der Meel
R. van der Meel
MSM. H. Symons
M. H. Symons
MFM. H. A. M. Fens
M. H. A. M. Fens
EPE. Pieters
E. Pieters
ABAnnette T Byrne
Annette T Byrne

6 November 2014 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MJMonika Jarzabek
Monika Jarzabek
VAV Amberger-Murphy
V Amberger-Murphy
JCJ J Callanan
J J Callanan
CGC Gao
C Gao
AZA M Zagozdzon
A M Zagozdzon
ABAnnette T Byrne
Annette T Byrne
Glioblastoma (GBM), being a highly vascularised and locally invasive tumour, is an attractive target for anti-angiogenic and anti-invasive therapies. The GBM/endothelial cell response to gossypol/temozolomide (TMZ) treatment was investigated with a particular aim to assess treatment effects on cancer hallmarks. Cell viability, endothelial tube formation and GBM tumour cell invasion were variously assessed following combined treatment in vitro. The U87MG-luc2 subcutaneous xenograft model was used to investigate therapeutic response in vivo. Viable tumour response to treatment was interrogated using immunohistochemistry. Combined treatment protocols were also tested in primary GBM patient-derived cultures. An endothelial/GBM cell viability inhibitory effect, as well as an anti-angiogenic and anti-invasive response, to combined treatment have been demonstrated in vitro. A significantly greater anti-proliferative (P=0.020, P=0.030), anti-angiogenic (P=0.040, P<0.0001) and pro-apoptotic (P=0.0083, P=0.0149) response was observed when combined treatment was compared with single gossypol/TMZ treatment response, respectively. GBM cell line and patient-specific response to gossypol/TMZ treatment was observed. Our results indicate that response to a combined gossypol/TMZ treatment is related to inhibition of tumour-associated angiogenesis, invasion and proliferation and warrants further investigation as a novel targeted GBM treatment strategy.

27 January 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Alice Claire O'FarrellAlice Claire O'Farrell
Alice Claire O'Farrell
RERhys Evans
Rhys Evans
JSJohanna M. U. Silvola
Johanna M. U. Silvola
IMIan Miller
Ian Miller
ECEmer Conroy
Emer Conroy
ABAnnette T Byrne
Annette T Byrne
Sunitinib is a tyrosine kinase inhibitor approved for the treatment of multiple solid tumors. However, cardiotoxicity is of increasing concern, with a need to develop rational mechanism driven approaches for the early detection of cardiac dysfunction. We sought to interrogate changes in cardiac energy substrate usage during sunitinib treatment, hypothesising that these changes could represent a strategy for the early detection of cardiotoxicity. Balb/CJ mice or Sprague-Dawley rats were treated orally for 4 weeks with 40 or 20 mg/kg/day sunitinib. Cardiac positron emission tomography (PET) was implemented to investigate alterations in myocardial glucose and oxidative metabolism. Following treatment, blood pressure increased, and left ventricular ejection fraction decreased. Cardiac [18F]-fluorodeoxyglucose (FDG)-PET revealed increased glucose uptake after 48 hours. [11C]Acetate-PET showed decreased myocardial perfusion following treatment. Electron microscopy revealed significant lipid accumulation in the myocardium. Proteomic analyses indicated that oxidative metabolism, fatty acid β-oxidation and mitochondrial dysfunction were among the top myocardial signalling pathways perturbed. Sunitinib treatment results in an increased reliance on glycolysis, increased myocardial lipid deposition and perturbed mitochondrial function, indicative of a fundamental energy crisis resulting in compromised myocardial energy metabolism and function. Our findings suggest that a cardiac PET strategy may represent a rational approach to non-invasively monitor metabolic pathway remodeling following sunitinib treatment.

1 August 2014 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
KSKieron J. Sweeney
Kieron J. Sweeney
MJMonika Jarzabek
Monika Jarzabek
PDPatrick Dicker
Patrick Dicker
DODonncha F. O’bRien
Donncha F. O’bRien
JCJohn J. Callanan
John J. Callanan
Jochen PrehnJochen Prehn
Jochen Prehn

1 May 2013 in Molecular Imaging
Verified
Journal Article
Open access
MJMonika Jarzabek
Monika Jarzabek
PHPeter C. Huszthy
Peter C. Huszthy
KSKai O. Skaftnesmo
Kai O. Skaftnesmo
ECEmmet Mc Cormack
Emmet Mc Cormack
PDPatrick Dicker
Patrick Dicker
ABAnnette T Byrne
Annette T Byrne
Glioblastoma multiforme (GBM), the most aggressive brain malignancy, is characterized by extensive cellular proliferation, angiogenesis, and single-cell infiltration into the brain. We have previously shown that a xenograft model based on serial xenotransplantation of human biopsy spheroids in immunodeficient rodents maintains the genotype and phenotype of the original patient tumor. The present work further extends this model for optical assessment of tumor engraftment and growth using bioluminescence imaging (BLI). A method for successful lentiviral transduction of the firefly luciferase gene into multicellular spheroids was developed and implemented to generate optically active patient tumor cells. Luciferase-expressing spheroids were injected into the brains of immunodeficient mice. BLI photon counts and tumor volumes from magnetic resonance imaging (MRI) were correlated. Luciferase-expressing tumors recapitulated the histopathologic hallmarks of human GBMs and showed proliferation rates and microvessel density counts similar to those of wild-type xenografts. Moreover, we detected widespread invasion of luciferase-positive tumor cells in the mouse brains. Herein we describe a novel optically active model of GBM that closely mimics human pathology with respect to invasion, angiogenesis, and proliferation indices. The model may thus be routinely used for the assessment of novel anti-GBM therapeutic approaches implementing well-established and cost-effective optical imaging strategies.